Tempus AI Inc. Unveils xM Assay to Enhance Monitoring of Immunotherapy Response in Advanced Cancer Patients

Reuters

2025/06/02

<a href="https://laohu8.com/S/TEM">Tempus AI</a> Inc. Unveils xM Assay to Enhance Monitoring of Immunotherapy Response in Advanced Cancer Patients

Tempus AI Inc. has announced the introduction of xM for treatment response monitoring $(TRM.AU)$, a liquid biopsy assay designed to detect molecular response to immune-checkpoint inhibitor $(ICI.AU)$ therapy in advanced solid tumors. This new assay is part of Tempus' expanding portfolio aimed at monitoring molecular response and minimal residual disease $(MRD.AU)$. Currently available for research use only, clinical availability is anticipated later this year. The xM for TRM assay tracks changes in circulating tumor DNA (ctDNA) dynamics over time, enabling early assessment of molecular response in patients undergoing ICI treatments. Tempus is set to present new data on xM for TRM at the 2025 American Society of Clinical Oncology (ASCO®) Annual Meeting, emphasizing the assay's potential to aid clinicians in monitoring treatment response and refining therapeutic strategies for patients with advanced cancers.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tempus AI Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250602186479) on June 02, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2540174798"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2540174798\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2540174798?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-02 20:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2540174798","market":"us","top_or_hot":-1,"title":"Tempus AI Inc. Unveils xM Assay to Enhance Monitoring of Immunotherapy Response in Advanced Cancer Patients","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/TEM\">Tempus AI</a> Inc. Unveils xM Assay to Enhance Monitoring of Immunotherapy Response in Advanced Cancer Patients\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Tempus AI Inc. has announced the introduction of xM for treatment response monitoring <a href=\"https://laohu8.com/S/TRM.AU\">$(TRM.AU)$</a>, a liquid biopsy assay designed to detect molecular response to immune-checkpoint inhibitor <a href=\"https://laohu8.com/S/ICI.AU\">$(ICI.AU)$</a> therapy in advanced solid tumors. This new assay is part of Tempus' expanding portfolio aimed at monitoring molecular response and minimal residual disease <a href=\"https://laohu8.com/S/MRD.AU\">$(MRD.AU)$</a>. Currently available for research use only, clinical availability is anticipated later this year. The xM for TRM assay tracks changes in circulating tumor DNA (ctDNA) dynamics over time, enabling early assessment of molecular response in patients undergoing ICI treatments. Tempus is set to present new data on xM for TRM at the 2025 American Society of Clinical Oncology (ASCO®) Annual Meeting, emphasizing the assay's potential to aid clinicians in monitoring treatment response and refining therapeutic strategies for patients with advanced cancers.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tempus AI Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250602186479) on June 02, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tempus AI Inc. Unveils xM Assay to Enhance Monitoring of Immunotherapy Response in Advanced Cancer Patients</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTempus AI Inc. Unveils xM Assay to Enhance Monitoring of Immunotherapy Response in Advanced Cancer Patients\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-06-02 20:30</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/TEM\">Tempus AI</a> Inc. Unveils xM Assay to Enhance Monitoring of Immunotherapy Response in Advanced Cancer Patients\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Tempus AI Inc. has announced the introduction of xM for treatment response monitoring <a href=\"https://laohu8.com/S/TRM.AU\">$(TRM.AU)$</a>, a liquid biopsy assay designed to detect molecular response to immune-checkpoint inhibitor <a href=\"https://laohu8.com/S/ICI.AU\">$(ICI.AU)$</a> therapy in advanced solid tumors. This new assay is part of Tempus' expanding portfolio aimed at monitoring molecular response and minimal residual disease <a href=\"https://laohu8.com/S/MRD.AU\">$(MRD.AU)$</a>. Currently available for research use only, clinical availability is anticipated later this year. The xM for TRM assay tracks changes in circulating tumor DNA (ctDNA) dynamics over time, enabling early assessment of molecular response in patients undergoing ICI treatments. Tempus is set to present new data on xM for TRM at the 2025 American Society of Clinical Oncology (ASCO®) Annual Meeting, emphasizing the assay's potential to aid clinicians in monitoring treatment response and refining therapeutic strategies for patients with advanced cancers.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tempus AI Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250602186479) on June 02, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4613","symbol_name":"AI應用軟件","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250602:nNDLbQy3MV:1","article_id":"2540174798","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2540174798","pubTimestamp":1748867414,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Tempus AI Inc. has announced the introduction of xM for treatment response monitoring , a liquid biopsy assay designed to detect molecular response to immune-checkpoint inhibitor  therapy in advanced solid tumors. This new assay is part of Tempus' expanding portfolio aimed at monitoring molecular response and minimal residual disease . Currently available for research use only, clinical availability is anticipated later this year. The xM for TRM assay tracks changes in circulating tumor DNA  dynamics over time, enabling early assessment of molecular response in patients undergoing ICI treatments. Tempus is set to present new data on xM for TRM at the 2025 American Society of Clinical Oncology  Annual Meeting, emphasizing the assay's potential to aid clinicians in monitoring treatment response and refining therapeutic strategies for patients with advanced cancers.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4613":"AI应用软件","LU1861559042.SGD":"日兴方舟颠覆性创新基金B SGD","LU1861558580.USD":"日兴方舟颠覆性创新基金B","TEM":"Tempus AI","BK4611":"AI医疗","BK4121":"生命科学工具和服务"},"translate_title":"Tempus AI Inc.推出xM Assay以增强对晚期癌症患者免疫治疗反应的监测","themeId":"715ea2be3c240e157af090fc4d598bc8","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TEM":0.9},"content_text":"Tempus AI Inc. Unveils xM Assay to Enhance Monitoring of Immunotherapy Response in Advanced Cancer Patients\n    \n\n        Tempus AI Inc. has announced the introduction of xM for treatment response monitoring $(TRM.AU)$, a liquid biopsy assay designed to detect molecular response to immune-checkpoint inhibitor $(ICI.AU)$ therapy in advanced solid tumors. This new assay is part of Tempus' expanding portfolio aimed at monitoring molecular response and minimal residual disease $(MRD.AU)$. Currently available for research use only, clinical availability is anticipated later this year. The xM for TRM assay tracks changes in circulating tumor DNA (ctDNA) dynamics over time, enabling early assessment of molecular response in patients undergoing ICI treatments. Tempus is set to present new data on xM for TRM at the 2025 American Society of Clinical Oncology (ASCO®) Annual Meeting, emphasizing the assay's potential to aid clinicians in monitoring treatment response and refining therapeutic strategies for patients with advanced cancers.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tempus AI Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250602186479) on June 02, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}